Infliximab plus azathioprine for children with Crohn's
Part of Digestive system clinical trials.
This study tests a combination of two drugs, infliximab and azathioprine, to see if it works better than either drug alone for children with moderate to severe Crohn's disease. The trial is for children who have not used these drugs before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of Crohn's disease based on expert guidelines for children.
- Your Crohn's disease symptoms must be moderate to severe, as measured by a special score (PCDAI of 30 or higher).
- You must not have taken azathioprine, 6-mercaptopurine, or anti-TNF drugs (like infliximab) before.
- You may use stable doses of acid-reducing drugs or have a steady enteral nutrition plan for at least 2 weeks before starting.
- You cannot have used corticosteroids (by mouth, vein, or rectum) for at least 2 weeks before the trial starts.
- You must not have certain conditions like short bowel syndrome, recent major abdominal surgery, active infections like tuberculosis, or certain gene mutations (NUDT15 or TPMT).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a special gut bacteria (Akkermansia muciniphila) to the standard biologic treatment infliximab can help heal the lining of the intestine better than infliximab alone. It is for people with active Crohn's disease who have not used biologics or antibiotics recently.
This trial studies a combination of immune-suppressing treatments for children with Crohn’s disease that is not well controlled. It may help reduce inflammation and improve symptoms if you meet the study’s disease-activity and safety requirements.
This study keeps track of how infliximab works and how safe it is in Chinese children with moderate-to-severe active Crohn’s disease. You may be eligible if this is the first time your child is starting infliximab and you agree to provide study information.
This study tests if a special diet (called CDED) combined with infliximab (a biologic drug) is more effective than infliximab alone for children with newly diagnosed or relapsed moderate-to-severe Crohn’s disease. It aims to improve gut healing and reduce inflammation.
This study measures how infliximab (a medicine that calms immune inflammation) moves through the body in children with Crohn’s disease. It mainly helps doctors understand dosing and drug levels, especially when treatment is newly starting.
This trial tests a more precise way to start infliximab (a Crohn’s medicine) and adjust dosing based on how your body responds. It aims to better control Crohn’s inflammation early and keep it under control.
Hear when a new Crohn's Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.